Co-Authors
This is a "connection" page, showing publications co-authored by STEVEN I SHERMAN and ROBERT F GAGEL.
Connection Strength
1.010
-
ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther. 2021 04; 20(4):665-675.
Score: 0.200
-
Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Mol Cancer Res. 2019 03; 17(3):751-760.
Score: 0.173
-
Thyroid carcinoma. J Natl Compr Canc Netw. 2007 Jul; 5(6):568-621.
Score: 0.078
-
Thyroid carcinoma. J Natl Compr Canc Netw. 2005 May; 3(3):404-57.
Score: 0.067
-
Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328.
Score: 0.047
-
Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402.
Score: 0.041
-
Evaluation of the incidental adrenal mass. Am J Med. 1997 Sep; 103(3):249-50.
Score: 0.039
-
Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 2016 12; 26(12):1744-1751.
Score: 0.037
-
Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877.
Score: 0.037
-
Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106.
Score: 0.032
-
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42.
Score: 0.028
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
Score: 0.026
-
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8.
Score: 0.023
-
Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head Neck. 2009 Mar; 31(3):419-23.
Score: 0.022
-
Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid. 2008 Aug; 18(8):901-5.
Score: 0.021
-
Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab. 2006 Jun; 91(6):2205-8.
Score: 0.018
-
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005 Jun; 15(6):531-44.
Score: 0.017
-
Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
Score: 0.016
-
Surgical management of hereditary pheochromocytoma. J Am Coll Surg. 2004 Apr; 198(4):525-34; discussion 534-5.
Score: 0.016
-
Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003 Dec; 134(6):890-9; discussion 899-901.
Score: 0.015
-
Potential role for intraoperative gamma probe identification of normal parathyroid glands. Am J Surg. 2003 Dec; 186(6):711-7.
Score: 0.015
-
Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003 Apr; 138(4):409-16; discussion 416.
Score: 0.015
-
Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression. Surgery. 2002 Dec; 132(6):968-74; discussion 974-5.
Score: 0.014
-
Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg. 2002 Jun; 137(6):641-7.
Score: 0.014